Disc Medicine (IRON) Accumulated Expenses (2020 - 2026)
Disc Medicine (IRON) reported Accumulated Expenses of $6.8 million for Q1 2026, up 276.56% year-over-year from $1.8 million in Q1 2025, and down 46.0% on a QoQ basis from $12.6 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Accumulated Expenses data on file, last reported at $6.8 million in Q1 2026.
- Quarterly Accumulated Expenses rose 276.56% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 276.56% YoY) and the FY2025 annual result came in at $12.6 million, up 75.32% from the prior year.
- Accumulated Expenses eased to $6.8 million in Q1 2026 per IRON's latest filing, from $12.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $12.6 million in Q4 2025 and bottomed at $325000.0 in Q3 2022.
- The 5-year median for Accumulated Expenses is $4.0 million (2023), against an average of $5.1 million.
- The widest annual swing landed in 2022, when Accumulated Expenses plunged 95.17%; it then soared 876.31% in 2023.
- Tracing IRON's Accumulated Expenses over 5 years: stood at $3.6 million in 2022, then surged by 70.0% to $6.2 million in 2023, then climbed by 17.08% to $7.2 million in 2024, then surged by 75.32% to $12.6 million in 2025, then slumped by 46.0% to $6.8 million in 2026.
- Per Business Quant, the three latest IRON Accumulated Expenses figures stand at $6.8 million (Q1 2026), $12.6 million (Q4 2025), and $9.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.83 Mn |
| Dec 31, 2025 | 12.64 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 6.16 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Dec 31, 2024 | 7.21 Mn |
| Sep 30, 2024 | 5.51 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 8.82 Mn |
| Dec 31, 2023 | 6.16 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 2.12 Mn |
| Mar 31, 2023 | 4.03 Mn |
| Dec 31, 2022 | 3.62 Mn |
| Sep 30, 2022 | 325,000.00 |
| Jun 30, 2022 | 1.91 Mn |
| Mar 31, 2022 | 3.41 Mn |
| Dec 31, 2021 | 4.10 Mn |
| Sep 30, 2021 | 6.72 Mn |
| Jun 30, 2021 | 5.01 Mn |
| Mar 31, 2021 | 5.21 Mn |
| Dec 31, 2020 | 5.81 Mn |
| Sep 30, 2020 | 461,999.00 |